The global impact of Precision Medicine Group.
As it happens.
Impact, observations, and insights on the evolving healthcare landscape.
In Part 1 of a two-part series, Todd Edgar, Alex Grosvenor, and Kellie Rademacher discuss EU biosimilar policies and their impact on the US approach, with a focus on payer coverage. (more…)
In an original article appearing in Journal of Clinical Pathways, Ashwin Athri, SVP Precision Promotional Effectiveness, discusses how variations in health systems influence oncology practices. (more…)
The February issue of All Access, Precision’s free newsletter featuring articles by former payers written specifically for market access leaders, is now available. (more…)
Precision for Medicine’s Jared Kohler and Tobias Guennel highlight the challenges for researchers pursuing biomarkers and specialty lab data that meet new FDA regulatory standards. (more…)
In a new commentary for Pharmaceutical Market Europe, Precision for Value’s Austin Speier, VP, Emerging Technology, examines the promise and advantages of integrating digital biomarkers into precision medicine. (more…)
In an in-depth commentary for Pharmaceutical Market Europe, senior economist Jason Shafrin argues for real-world evidence (RWE) to become the “gold standard” of scientific evidence and heath technology assessments. (more…)
Chief Medical Officer Gerry Messerschmidt authors a new commentary in Biocompare outlining critical success factors toward cancer vaccine development. (more…)
Rare Disease Report interviews Chief Medical Officer Gerald Messerschmidt while at the American Society of Hematology Annual Meeting. (more…)
Precisioneffect Chief Creative Officer Deborah Lotterman pens a new commentary in the latest edition of MedAd News, “Making Sense of the Irrational.” (more…)
Senior Vice President Jeremy Schafer and Chief Creative Officer Deborah Lotterman submit a new commentary to MedAd News,“Enriching the Patient Journey: When Cost Creates Side Effects.” (more…)